Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A3MQR65
Mon, 23.06.2025
Viromed Medical AG
Viromed Medical AG: Cold plasma technology shows potential to significantly reduce deaths in ventilated patients
Pinneberg, June 23, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has been informed by the Hannover Medical School (“Medizinische Hochschule Hannover“; MHH [ … ]
Fri, 06.06.2025
Viromed Medical AG
Viromed Medical AG plans change in the Supervisory Board and Chairman of the Supervisory Board
Pinneberg, June 06, 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer in cold plasma technology, proposes to the Annual General Meeting on July 29, 2025 that Dr. Thomas Gutschlag be elected [ … ]
Thu, 15.05.2025
Viromed Medical AG
Viromed Medical AG: Revolutionary cold plasma therapy for the treatment of ventilator-associated pneumonia (VAP) shows 100% efficacy in an in vitro study with MRSA and human lung cells (alveoli)
Study confirms the effectiveness and safety of cold plasma therapy
Pinneberg, May 14, 2025 - Viromed Medical AG ("Viromed", FSE: VMED; ISIN: DE000A3MQR65) [ … ]
Fri, 25.04.2025
Viromed Medical AG
Exclusive contract for ViroCAP® My Plasma with Landsberg First Class Aesthetic opens up Viromed's entry into the European cosmetics market
Pinneberg, April 25, 2025 - Viromed Medical AG ("Viromed", Ticker: VMED; ISIN: DE000A3MQR65), a medical device company and pioneer in cold plasma technology, and Landsberg First Class Aesthetic ("Landsberg"), [ … ]
Wed, 23.04.2025
Viromed Medical AG
Viromed Medical AG welcomes Dr. Thomas Gutschlag as new Investor
Pinneberg, April 23, 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in wound healing, intensive care medicine and air disinfection, has gained Dr. Thomas Gutschlag, founder [ … ]
Thu, 10.04.2025
Viromed Medical AG
Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP® VET for veterinary use
Pinneberg, April 10. April 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in wound healing, intensiv [ … ]
Tue, 01.04.2025
Viromed Medical AG
Viromed Medical AG: UMECO Group acquires exclusive marketing rights in Asia for cold plasma medical devices ViroCAP® and PulmoPlas®
Pinneberg, 01. April 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in air disinfection, wound healing an [ … ]
Fri, 14.03.2025
Viromed Medical AG
Viromed Medical AG reports promising study results for PulmoPlas® in intensive care unit ventilator-associated pneumonia patients
Pinneberg, Germany, March 14, 2025 - Viromed Medical AG (“Viromed”, Ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in room air sterilization, woun [ … ]
Fri, 07.03.2025
Viromed Medical AG
Viromed Medical AG: Strategic healthcare investor acquires further shares in private placement
Pinneberg, 7 March 2025 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has been informed by its majority shareholder (together with his wife) and CEO Uwe Perbandt about a further off-market placement of a total of 900,000 shares from his holdings [ … ]
Fri, 28.02.2025
Viromed Medical AG
Viromed Medical AG reaches milestone for cooperation with multinational corporation
Pinneberg, 28 February 2025 –Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded [ … ]